TABLE 3.
Details of bleeding events, stratified by risk and timing of VTE event
| Number | Type of bleed | Malignancy | Platelet count at time of bleed (×103/µL) | Days since last platelet transfusion | Anticoagulant used at time of bleed |
|---|---|---|---|---|---|
| Preintervention group | |||||
| 1 | Epistaxis, gingival bleeding | Solid Tumor | 37 | >30 | Apixaban |
| Postintervention, high‐risk VTE <30 days | |||||
| 1 | Retroperitoneal hematoma a | Lymphoma | 24 | >30 | Unfractionated heparin |
| 2 | GI Bleed a | Lymphoma | 58 | >30 | Enoxaparin |
| 3 | Tracheostomy a | AML/MDS | 35 | 1 | Enoxaparin |
| 4 | Subdural Hematoma a | AML/MDS | 64 | 1 | Enoxaparin |
| 5 | GI bleed | AML/MDS | 50 | >30 | Apixaban |
| Postintervention, low‐risk VTE <30 days | |||||
| 6 | Retroperitoneal Hematoma | Lymphoma | 123 | 1 | Enoxaparin |
| 7 | Renal subcapsular hematoma a | Myeloma, BMT | 101 | >30 | Enoxaparin |
| 8 | Hematochezia | Myeloma | 69 | 1 | Enoxaparin |
| Postintervention, high‐risk VTE >30 days | |||||
| 9 | Pelvic wall hematoma | Lymphoma | 56 | >30 | Warfarin |
| 10 | Hemoptysis | Solid Tumor | 15 | >30 | Enoxaparin |
| 11 | Epistaxis | Solid Tumor | 9 | 19 | Enoxaparin |
| 12 | Subarachnoid hemorrhage a | Lymphoma | 46 | 6 | Apixaban |
| Postintervention, low‐risk VTE >30 days | |||||
| 13 | GI bleed | Solid tumor | 52 | 2 | Enoxaparin |
Abbreviations: AML, acute myeloid leukemia; BMT, bone marrow transplant; GI, gastrointestinal; MDS, myelodysplastic syndrome; VTE, venous thromboembolism.
a
Denotes bleed was considered a major bleed.